HC Wainwright & Co. Maintains Buy on Iterum Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Iterum Therapeutics (NASDAQ:ITRM) but lowers the price target from $6 to $5.
August 15, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Iterum Therapeutics but lowers the price target from $6 to $5.
The Buy rating suggests continued confidence in Iterum Therapeutics, but the lowered price target indicates a tempered outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100